Gene therapy: progress and challenges.
Gene therapy is the delivery of new genetic material into a patient's somatic cells for the treatment of disease and is made possible through the development of viral and non-viral gene transfer vectors. In the first five years of gene therapy, clinical studies failed to yield efficacy data with the vectors available at that time. The lack of consistent clinical benefit prompted the United States National Institute of Health Recombinant DNA Advisory Committee to evaluate gene therapy research and conclude that substantial improvements in gene transfer vectors were needed in the areas of vector safety and control of the level and duration of gene expression, and to increase the understanding of the biological interaction of gene transfer vectors with the host. We will describe the progress in development of gene delivery technology, focusing on improvements in vector safety, analysis of vector biodistribution and GMP manufacturing of viral and non-viral gene transfer systems over the last six years since the report. Whereas 5 years ago, investigators tested every vector for every potential disease indication, the accumulated database now enables investigators to select a single vector based upon it's known performance in a wide number of animal models and human clinical studies. We will also highlight several directions investigators have taken to improve the safety and efficacy of gene therapy vectors.
Meyer
F
F
Aventis Pharma/Gencell, Vitry-s-Seine, France. francois.meyer@aventis.com
Finer
M
M
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D004247:DNA / Q000378:metabolism; D000229:Dependovirus / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends*; D005822:Genetic Vectors; D006801:Humans; D008957:Models, Genetic; D010957:Plasmids / Q000378:metabolism; D012190:Retroviridae / Q000235:genetics; D013997:Time Factors
D004247:DNA